These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37321375)

  • 21. An overview of rational design of mRNA-based therapeutics and vaccines.
    To KKW; Cho WCS
    Expert Opin Drug Discov; 2021 Nov; 16(11):1307-1317. PubMed ID: 34058918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA.
    Vlatkovic I; Ludwig J; Boros G; Szabó GT; Reichert J; Buff M; Baiersdörfer M; Reinholz J; Mahiny AJ; Şahin U; Karikó K
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections.
    Parums DV
    Med Sci Monit; 2021 May; 27():e932915. PubMed ID: 33942804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.
    Steinle H; Behring A; Schlensak C; Wendel HP; Avci-Adali M
    Stem Cells; 2017 Jan; 35(1):68-79. PubMed ID: 27250673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
    Vadovics M; Muramatsu H; Sárközy A; Pardi N
    Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a capillary zone electrophoresis method to monitor magnesium ion consumption during in vitro transcription for mRNA production.
    Wang Y; Li L; Sutton AT; Tu Q; Zhao K; Wen E; Osborn J; Singh A; Gunsch MJ; Rustandi RR; Foley D; He Y
    Anal Bioanal Chem; 2024 May; 416(12):2941-2949. PubMed ID: 38594392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery.
    Żak MM; Zangi L
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow-NMR as a Process-Monitoring Tool for mRNA IVT Reaction.
    Sarkar A; Dong G; Quaglia-Motta J; Sackett K
    J Pharm Sci; 2024 Apr; 113(4):900-905. PubMed ID: 38008177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.
    Kwon H; Kim M; Seo Y; Moon YS; Lee HJ; Lee K; Lee H
    Biomaterials; 2018 Feb; 156():172-193. PubMed ID: 29197748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N
    Mulroney TE; Pöyry T; Yam-Puc JC; Rust M; Harvey RF; Kalmar L; Horner E; Booth L; Ferreira AP; Stoneley M; Sawarkar R; Mentzer AJ; Lilley KS; Smales CM; von der Haar T; Turtle L; Dunachie S; Klenerman P; Thaventhiran JED; Willis AE
    Nature; 2024 Jan; 625(7993):189-194. PubMed ID: 38057663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and characterization of two SARS-CoV-2 minigenome replicon systems.
    Zhang H; Fischer DK; Shuda M; Moore PS; Gao SJ; Ambrose Z; Guo H
    J Med Virol; 2022 Jun; 94(6):2438-2452. PubMed ID: 35137972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo.
    Rybakova Y; Kowalski PS; Huang Y; Gonzalez JT; Heartlein MW; DeRosa F; Delcassian D; Anderson DG
    Mol Ther; 2019 Aug; 27(8):1415-1423. PubMed ID: 31160223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical Modifications of mRNA Ends for Therapeutic Applications.
    Warminski M; Mamot A; Depaix A; Kowalska J; Jemielity J
    Acc Chem Res; 2023 Oct; 56(20):2814-2826. PubMed ID: 37782471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic modified messenger RNA for therapeutic applications.
    Gao M; Zhang Q; Feng XH; Liu J
    Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the impact of
    Lenk R; Kleindienst W; Szabó GT; Baiersdörfer M; Boros G; Keller JM; Mahiny AJ; Vlatkovic I
    Front Mol Biosci; 2024; 11():1426129. PubMed ID: 39050733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.
    Johler SM; Rejman J; Guan S; Rosenecker J
    PLoS One; 2015; 10(9):e0137504. PubMed ID: 26352268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.